Published in Biotechnology Progress (Wiley/AICHE) — DOI: 10.1002/btpr.70108
Authors: Tiffany McLamarrah et al. (Sanofi, iBET, Demeetra)
Download the paper (PDF): https://aiche.onlinelibrary.
Why this matters for CHO-based biologics platforms
Most genome-editing case studies in CHO focus on single hosts or proof-of-concept targets. This new peer-reviewed study demonstrates what large-scale, platform-level genome engineering looks like in practice across a diverse panel of CHO‑K1 hosts—showing that Cas‑CLOVER can be applied enterprise-wide to accelerate host optimization, de-risk CLD programs, and unlock higher productivity baselines.
Summary
- Scope: 30 distinct, serum‑free, suspension‑adapted CHO‑K1 hosts were edited at the glutamine synthetase (GS) locus using Cas-CLOVER.
- Throughput: Generated 100+ GS knockout (GSKO) clones, with 98 validated by three orthogonal methods.
- Stability: Cas‑CLOVER–mediated GS knockout clones and subclones remained stable over 63 days in culture.
- Editing efficiency: Up to 72% via nucleofection (reported in the paper’s supplementary data).
- Productivity impact: Up to 14.5-fold titer increase versus non-edited parental CHO cells in pooled production runs.
Key takeaway: Unlike standard CRISPR/Cas9, which often yields small 1–2 bp indels and relies on homozygous frameshifts, Cas‑CLOVER typically produces larger asymmetric deletions, enabling functional knockouts even in heterozygous clones—a feature that translated here into reliable GS knockouts across 28 of 30 CHO‑K1 host backgrounds in ~6 weeks.
What’s new about Cas‑CLOVER in this context?
Cas‑CLOVER is a dual‑guide, dCas9‑Clo051 nuclease system. Because cleavage requires obligate dimerization at two nearby target sites, it supports high specificity and often yields larger deletions than conventional Cas9, simplifying screening for true loss‑of‑function outcomes. Prior technical briefs and posters have highlighted this “larger deletions” behavior and its practical benefits in CHO cell engineering.
Study highlights
-
Enterprise‑scale host panel
The team applied a uniform editing strategy across 30 independent CHO‑K1 hosts maintained in serum‑free suspension, an uncommon scale that demonstrates broad deployability across platforms. - Editing throughput and validation rigor
100+ candidate GSKO clones were generated; 98 were confirmed GS knockouts via three orthogonal assays, supporting confident genotype–phenotype links. - Durable phenotype
Knockout stability through 63 days in culture addresses a common concern about edit durability during CLD. - Process‑relevant gains
Pooled mAb production with GSKO clones achieved up to 14.5× higher titers than parental hosts—an effect size that, if replicated in your platform, could reshape early CLD economics and timelines. - Mechanistic edge over Cas9
The authors attribute reliable knockouts—even when heterozygous—to Cas‑CLOVER’s tendency for larger asymmetric deletions, in contrast to the small indels typical of single‑guide Cas9.
External technical materials and prior presentations have documented Cas‑CLOVER’s larger‑deletion signature and high‑specificity, dual‑guide design, including CHO applications and GS‑knockout strategies. This paper adds peer-reviewed, multi-host, platform-scale evidence that those properties translate to consistent functional outcomes across diverse CHO‑K1 backgrounds.